vTv Therapeutics Inc.
VTVT Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$25.55
KIRA · Stoqly’s AI analyst, in plain words
- vTv Therapeutics Inc. had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- vTv Therapeutics Inc. lost $27.0M in fiscal 2025.
Market cap
—
P/E
—
Revenue
$0.0M
Net income
−$27.0M
Free cash flow
—
Operating margin
—
vTv Therapeutics Inc. in 30 seconds · fiscal 2025
Are sales growing?
−100.0%
No. Sales fell 100.0% last year.
Does it make a profit?
−$27.0M
No. It lost money last year.
What vTv Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- vTv Therapeutics Inc.
- CIK
- 0001641489
vTv Therapeutics Inc. · VTVT
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $4.0M | $2.0M | $0.0M | $1.0M | $0.0M |
| Revenue growth | −37.6% | −49.6% | −100.0% | — | −100.0% |
| Operating margin | −540.9% | −1,116.9% | — | −2,377.6% | — |
| Net income | −$13.0M | −$19.2M | −$20.3M | −$18.5M | −$27.0M |
| Net margin | −324.3% | −949.7% | — | −1,815.3% | — |
| Cash | |||||
| Cash from operations | −$19.3M | −$16.0M | −$19.1M | −$25.3M | −$25.3M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Free cash flow | −$19.3M | −$16.0M | −$19.1M | −$25.3M | — |
| FCF margin | −482.1% | −795.0% | — | −2,488.4% | — |
| Debt and strength | |||||
| Cash and short-term investments | $13.4M | $12.1M | $9.4M | $36.7M | $88.9M |
| Debt incl. finance leases | $0.3M | — | — | — | — |
| Shareholders' equity | −$9.7M | −$10.7M | −$24.7M | $12.2M | $64.4M |
| Current ratio | 1.8x | 3.5x | 1.0x | 7.3x | 13.5x |
| Interest coverage | −1,805.2x | −1,502.7x | −1,961.7x | — | — |
| Returns and quality | |||||
| Return on equity | — | — | — | — | −70.4% |
| Return on tangible equity | — | — | — | −151.3% | −41.9% |
| Piotroski F-score | 2 | — | — | — | — |
| Altman Z'' | −36.7 | −27.2 | −99.6 | −23.6 | −5.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
vTv Therapeutics Inc. · VTVT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $25.55 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001641489). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.